Welcome to our dedicated page for Mink Therapeutics news (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on Mink Therapeutics stock.
MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET. The event will be accessible live via a provided link, with a replay available on the MiNK website afterward. Recently, MiNK presented new data from five presentations at the Society for Immunotherapy of Cancer Annual Meeting on November 10th, showcasing their innovative iNKT cell therapies aimed at treating cancer and immune-mediated diseases.
MiNK Therapeutics announced promising results for its allogeneic iNKT cell therapy, agenT-797, showcasing early clinical activity in solid tumors with 27% of patients achieving disease stabilization alone and 66% in combination with pembrolizumab or nivolumab. Noteworthy is the survival benefit observed in viral ARDS patients, with a 70% survival rate versus 10% in controls. Moreover, agenT-797 demonstrated a favorable safety profile with no cytokine release syndrome reported, and the company is advancing new candidates for next-generation CAR-iNKT therapies.
MiNK Therapeutics reported third-quarter 2022 financial results, highlighting a net loss of $6.3 million ($0.19 per share), a significant reduction from a net loss of $14.3 million ($0.59 per share) in Q3 2021. The company had a cash balance of $24.2 million as of September 30, 2022, down from $38.9 million at the end of 2021. Operational cash usage increased, reflecting the internalization of cGMP manufacturing for clinical trials. The firm will present at the Society of Cancer Immunotherapy Meeting, showcasing clinical data on its iNKT cell therapies.
MiNK Therapeutics will release its third quarter 2022 financial results on November 3rd, 2022, before the market opens. A conference call is scheduled for 8:30 a.m. ET the same day, providing insights into the company's progress in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
The company focuses on scalable and reproducible manufacturing methods for its therapies, aiming for off-the-shelf delivery to patients.
MiNK Therapeutics is set to host a Research & Development Day on November 10, 2022, from 4:00 to 6:00 PM ET in Boston, MA, and via webcast. The event will highlight the company’s novel allogeneic iNKT cell therapy platform and feature insights from clinical trials and next-gen programs. Presentations will cover initial data from a phase 1 trial of iNKTs with anti-PD-1 inhibitors, as well as advancements in the FAP-CAR-iNKT program. The event will include leading immuno-oncology experts and is open to institutional investors.
MiNK Therapeutics announced the acceptance of five abstracts at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, scheduled for November 8-12, 2022. These abstracts focus on clinical data for AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy targeting advanced solid tumors, viral ARDS, and refractory multiple myeloma. New therapeutic candidates, MiNK-215 and MiNK-413, are also highlighted, showcasing advancements in CAR-iNKT therapy. The meeting will feature presentations from several experts, emphasizing the company's commitment to innovative cancer treatments.
MiNK Therapeutics, a biopharmaceutical firm focused on allogeneic iNKT cell therapies for cancer and immune diseases, will participate in two investor conferences this September. The HC Wainwright 24th Annual Global Investment Conference will feature a webcast on September 12th at 7:00 AM ET. Additionally, MiNK will participate in the Baird 2022 Global Healthcare Conference on September 14th at 1:25 PM ET. Both events will allow investors to explore MiNK's innovative therapies. Webcast replays will be available on the Company’s website.
MiNK Therapeutics reported its Q2 2022 financial results, highlighting ongoing advancements in its clinical programs, particularly AgenT-797 for cancer and viral ARDS. The company completed internal cGMP production capable of treating over 700,000 patients annually. Clinical data updates for AgenT-797 and a novel stromal-CAR-iNKT program are anticipated in the second half of 2022. Financially, MiNK ended Q2 with $29.8 million in cash and reported a net loss of $6.1 million, slightly improving from the previous year. The leadership team has also been expanded, notably appointing Dr. Joy Zhou as VP of CMC.
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will announce its Q2 2022 financial results prior to the market opening on August 9, 2022. A conference call is scheduled for 11:00 a.m. ET on the same day to discuss the results and provide corporate updates. MiNK specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies aimed at treating cancer and immune-mediated diseases, with a focus on scalable and reproducible manufacturing.